Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Major depressive disorder (MDD) affects about 10-15% of the general population in a lifetime. A considerable number of patients fail to achieve full symptom remission despite adequate treatment and are considered treatment resistant (TRD). The current study compared the relative efficacy and tolerability of pharmacological and somatic TRD interventions by means of a Bayesian network meta-analysis. RESEARCH DESIGN AND METHODS: An electronic literature search of MEDLINE, MEDLINE In-Process, EMBASE, PsycInfo, EconLit and Cochrane Library databases for trials published between September 2003 and September 2014 was conducted. Key outcomes extracted were disease severity change from baseline, response and remission rates at various timepoints and discontinuation due to adverse events. RESULTS: Of the 3876 abstracts identified, 31 publications/randomised controlled trials (RCTs) were included in the analysis; 19 RCTs investigating 13 pharmacological interventions and 12 RCTs investigating electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS). The evidence synthesis investigating efficacy outcomes of TRD treatments demonstrated superior efficacy for ketamine compared to pharmacological and somatic interventions at 2 weeks after treatment initiation. At 4, 6 and 8 weeks, quetiapine augmentation (800 mg/day) and risperidone augmentation were found to be the first and second best treatments, respectively. Networks were small for response rate and remission rate outcomes at most timepoints. The most tolerable treatment was lamotrigine augmentation showing a comparable profile to placebo/sham. CONCLUSIONS: This analysis revealed scarcity of long-term data on sustained remission that would allow a comparative long-term efficacy assessment. Key limitations of the analysis can be considered the search timeframe and the use of mapping formula for the depression scores.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, a network meta-analysis found that ketamine was superior to other pharmacological treatments at two weeks after treatment initiation; at four, six, and eight weeks, quetiapine and risperidone augmentation were found to be the best and second best treatments, respectively [71].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [71]
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
Combination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,166
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092
Evaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Jansen, J. P., Fleurence, R., Devine, B., Itzler, R., Barrett, A., Hawkins, N., Lee, K., Boersma, C., Annemans, L., & Cappelleri, J. C. (2011) · Value in Health · doi:10.1016/j.jval.2011.04.002 · Cited by 1,036
Hoaglin, D. C., Hawkins, N., Jansen, J. P., Scott, D. A., Itzler, R., Cappelleri, J. C., Boersma, C., Thompson, D., Larholt, K. M., Diaz, M., et al. (2011) · Value in Health · doi:10.1016/j.jval.2011.01.011 · Cited by 770
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
(1997) · PubMed · Cited by 727
Dias, S., Welton, N. J., Sutton, A. J., & Ades, A. E. (2011) · Bristol Research (University of Bristol) · Cited by 691
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Treatment-Resistant Depression
(2015) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-642-36172-2_200431 · Cited by 488
Fitzgerald, P. B., Hoy, K., McQueen, S., Maller, J. J., Herring, S., Segrave, R., Bailey, M., Been, G., Kulkarni, J., & Daskalakis, Z. J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.233 · Cited by 417
Berman, R. M., Marcus, R. N., Swanink, R., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Khan, A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0604 · Cited by 409
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Gaynes, B. N., Lloyd, S. W., Lux, L., Gartlehner, G., Hansen, R. A., Brode, S., Jonas, D. E., Evans, T. S., Viswanathan, M., & Lohr, K. N. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08815 · Cited by 347
Imputing response rates from means and standard deviations in meta-analyses
Furukawa, T. A., Cipriani, A., Barbui, C., Brambilla, P., & Watanabe, N. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200501000-00010 · Cited by 337
Lithium Augmentation in Treatment-Resistant Depression: Meta-Analysis of Placebo-Controlled Studies
Bauer, M., & Döpfmer, S. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00006 · Cited by 304
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260
Papakostas, G. I., Shelton, R. C., Smith, J., & Fava, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0602 · Cited by 241
Cooper, N. J., Sutton, A. J., Morris, D., Ades, A. E., & Welton, N. J. (2009) · Statistics in Medicine · doi:10.1002/sim.3594 · Cited by 237
Zimmerman, M., Posternak, M. A., & Chelminski, I. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.03.007 · Cited by 229
Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
Therapeutic Options for Treatment-Resistant Depression
Shelton, R. C., Osuntokun, O., Heinloth, A. N., & Corya, S. A. (2010) · CNS Drugs · doi:10.2165/11530280-000000000-00000 · Cited by 205
Zhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Del Giovane, C., Zhao, J., Liu, Y., Fang, Y., Zhang, Y., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv060 · Cited by 197
Zhou, X., Ravindran, A. V., Qin, B., Del Giovane, C., Li, Q., Bauer, M., Liu, Y., Fang, Y., da Silva, T., Zhang, Y., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09204 · Cited by 189
Corya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170
Corya, S. A. (2005) · doi:10.4088/jcp.v66n1012 · Cited by 162
Bayesian Measures of Model Complexity and Fit
Spiegelhalter, D. J., Best, N. G., Carlin, B. P., & Van Der Linde, A. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00353 · Cited by 151
Rossini, D., Lucca, A., Zanardi, R., Magri, L., & Smeraldi, E. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2005.06.008 · Cited by 127
Blumberger, D. M., Mulsant, B. H., Fitzgerald, P. B., Rajji, T. K., Ravindran, A. V., Young, L. T., Levinson, A. J., & Daskalakis, Z. J. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.579163 · Cited by 118
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
Fitzgerald, P. B., Hoy, K. E., Herring, S. E., McQueen, S., Peachey, A., Segrave, R. A., Maller, J. J., Hall, P. J., & Daskalakis, Z. J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.02.017 · Cited by 113
Pallanti, S., Bernardi, S., Rollo, A. D., Antonini, S., & Quercioli, L. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.063 · Cited by 111
Cope, S., Zhang, J., Saletan, S., Smiechowski, B., Jansen, J. P., & Schmid, P. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-93 · Cited by 110
Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants
Nierenberg, A. A., Papakostas, G. I., Petersen, T., Montoya, H. D., Worthington, J. J., Tedlow, J., Alpert, J. E., & Fava, M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00013 · Cited by 103
Reeves, H., Batra, S., May, R. S., Zhang, R., Dahl, D. C., & Li, X. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0805 · Cited by 102
García-Toro, M., Salvá, J., Daumal, J., Andres, J., Romera, M., Lafau, O., Echevarría, M., Mestre, M., Bosch, C., Collado, C. T., et al. (2005) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.08.005 · Cited by 99
Rosa, M. A., Gattaz, W. F., Pascual-Leone, A., Fregni, F., Rosa, M. O., Rumi, D. O., Myczkowski, M., Silva, M. F., Mansur, C., Rigonatti, S. P., et al. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007127 · Cited by 88
Quetiapine augmentation of treatment-resistant depression: a comparison with lithium
Dorée, J.-P., Rosiers, J. D., Lew, V., Gendron, A., Elie, R., Stip, E., & Valérie Tourjman, S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162809 · Cited by 84
Zheng, H., Zhang, L., Li, L., Liu, P., Gao, J., Liu, X., Zou, J., Zhang, Y., Liu, J., Zhang, Z., et al. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.009 · Cited by 80
Clinical trials and the response rate illusion
Kirsch, I., & Moncrieff, J. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.10.012 · Cited by 80
Triggs, W. J., Ricciuti, N., Ward, H. E., Cheng, J., Bowers, D., Goodman, W. K., Kluger, B. M., & Nadeau, S. E. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.05.009 · Cited by 74
Papakostas, G. I., Nelson, J. C., Kasper, S., & Möller, H.-J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.005 · Cited by 73
An interactive computer-administered self-assessment and self-help program for behavior therapy.
Baer, L., & Greist, J. H. (1997) · PubMed · Cited by 69
Classification of Depression: Research and Diagnostic Criteria: DSM‐IV and ICD‐10
Gruenberg, A. M., Goldstein, R. D., & Pincus, H. A. (2005) · Biology of Depression · doi:10.1002/9783527619672.ch1 · Cited by 68
Schindler, F., & Anghelescu, I. G. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328014823d · Cited by 65
Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons
Jansen, J. P., Schmid, C. H., & Salanti, G. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.002 · Cited by 65
Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822bb1d9 · Cited by 59
Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., et al. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e7784f · Cited by 54
Santos, M. A., Rocha, F. L., & Hara, C. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0302 · Cited by 51
Therapy-Resistant Depressions – A Clinical Classification
Lehmann, H. E. (1974) · Pharmacopsychiatry · doi:10.1055/s-0028-1094425 · Cited by 46
Chen, S.-T., Shaw-Ji, C., Chun-Hung, C., Hsin-Chi, T., & Lin, C. C. H. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s40466 · Cited by 36
Bakim, B., Uzun, U. E., Karamustafalioglu, O., Ozcelik, B., Alpak, G., Tankaya, O., Cengiz, Y., & Yavuz, B. G. (2012) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20120807092434 · Cited by 28
Description and Classification of Depressive Disorders
Sartorius, N. (1974) · Pharmacopsychiatry · doi:10.1055/s-0028-1094404 · Cited by 17
Li, X., Xing, B., Yu, E., Chen, W., & Wu, H. (2013) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12070171 · Cited by 9
Liu, Q., Ji Jun, W. A. N. G., Li Wei, W. A. N. G., ZHANG, X. H., & Ye, F. (2011) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3969/j.issn.1002-0829.2011.01.005 · Cited by 5
Martín, M. F., Figueira, M. L., Petrov, P., Rihmer, Z., Vavrusova, L., Vansvik, E. D., Jörgensen, L., Köhler, J., & Bauer, M. W. (2010) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(10)70480-6 · Cited by 2
Research works printed but not linked: 6
- Thase MERA., 1997, J Clin Psychiatry, 58, 23
- Souery DPG, 2006, J Clin Psychiatry, 67, 16
- 2009, Symbyax
- Singh J, 2014, Biol Psychiatry, 1, 44S
- Thase MEFMHM, 2011, ACNP 50th Annual Meeting
- Zhang XHWLW, 2011, Shanghai Arch Psychiatry, 17
Cited by
Defining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447
Dandekar, M. P., Fenoy, A. J., Carvalho, A. F., Soares, J. C., & Quevedo, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2018.2 · Cited by 266
Ketamine and depression: a narrative review
Corriger, A., & Pickering, G. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s221437 · Cited by 211
“was no available data for ketamine efficacy at 4, 6, and 8 weeks in a meta-analysis.(32) Concerning remitters rate,”
BackgroundWalsh, Z., Mollaahmetoglu, O. M., Rootman, J., Golsof, S., Keeler, J., Marsh, B., Nutt, D. J., & Morgan, C. J. A. (2022) · BJPsych Open · doi:10.1192/bjo.2021.1061 · Cited by 186
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Metadata
- Authors
- Papadimitropoulou, K., Vossen, C., Karabis, A., Donatti, C., & Kubitz, N.
- Affiliations
- Mapi Group, Houten, Netherlands;
- Janssen (United Kingdom) (GB)
- Janssen-Cilag GmbH, Neuss, Germany
- Corresponding author
- Papadimitropoulou, Katerina
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2017-02-06
- Volume
- 33
- Issue
- 4
- Pages
- 701-711
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2567253990
- Cited by
- 91
- References
- 68
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 8 · 2023: 5 · 2022: 8 · 2021: 20 · 2020: 12 · 2019: 10 · 2018: 9 · 2017: 5
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- treatment-resistant depression, major depressive disorder, electroconvulsive therapy, repetitive transcranial magnetic stimulation, ketamine, pharmacological interventions, somatic interventions, treatment response, remission, tolerability, adverse events
- MeSH terms
- Network Meta-Analysis, Adult, Bayes Theorem, Major Depressive Disorder, Depressive Disorder, Major, Humans, Psychotropic Drugs, Remission Induction, Time, Treatment Outcome, Transcranial Magnetic Stimulation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.